Skip to content
AnalystLens

Cigna Group 8-K Report, Financial Results (Jan 30, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed January 30, 2025
Period End
January 30, 2025
Security
CI
In the record · 2018–202610-K810-Q238-K136

CI filed 8 annual reports (10-K), 23 quarterly reports (10-Q) and 136 current reports (8-K) between 2018 and 2026.

  1. Deal closed8-K · Feb ’19Feb ’19
  2. Material agreement8-K · Apr ’21Apr ’21
  3. Leadership change8-K · Sep ’23Sep ’23
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed January 30, 2025. Cited figures are marked; the original filing is the authoritative source.

The Cigna Group reported fourth quarter and full year 2024 results on January 30, 2025, with total revenues up 27% for the year to $247.1 billiona, driven mainly by Evernorth Health Services.

However, GAAP shareholders' net income fell sharply to $3.4 billionb, or $12.12 per share, from $5.2 billion ($17.39 per share) in 2023, primarily due to a non-cash after-tax $2.7 billion ($9.53 per share) investment loss tied to the impairment of VillageMD equity securities. On an adjusted basis, full-year income from operations rose 4% to $7.7 billion ($27.33 per share), but fourth-quarter adjusted income declined 8% to $1.8 billion ($6.64 per share), as Cigna Healthcare's stop loss medical costs pushed its medical care ratio to 87.9% in the quarter. Evernorth remained the growth engine, with adjusted revenues up 32% for the year and adjusted pre-tax income up 9%, supported by client wins, specialty volume growth and Humira biosimilar adoption.

Cigna Healthcare adjusted pre-tax income fell 6% for the year and 47% in the fourth quarter. Management is taking corrective actions on stop loss pricing and costs. Capital return remains a priority: the company repurchased 20.9 million shares for about $7.0 billionc in 2024, the board added $6.0 billion of repurchase authority (total $10.3 billion), and the quarterly dividend rises 8% to $1.51.

For 2025, Cigna guided to adjusted income from operations of at least $7.9 billiond, or at least $29.50 per share, with a Cigna Healthcare medical care ratio of 83.2% to 84.2%. The outlook assumes the divestiture of the Medicare businesses to HCSC closes in the first quarter of 2025. Investors should weigh the strong Evernorth growth and capital returns against the stop loss margin pressure and the recurring-looking charges in the GAAP results.

02—Key points

Key Highlights

  1. Total 2024 revenues rose 27% to $247.1 billion, driven by Evernorth Health Services growth from large client wins and strong specialty volume.
  2. GAAP shareholders' net income fell to $3.4 billion ($12.12 per share) from $5.2 billion ($17.39 per share), including a $2.7 billion after-tax non-cash loss on the VillageMD equity impairment.
  3. Adjusted income from operations rose 4% for 2024 to $7.7 billion ($27.33 per share), but fourth-quarter adjusted income fell 8% to $1.8 billion ($6.64 per share).
  4. Cigna Healthcare's MCR was 87.9% in Q4 2024 and 83.2% for the full year, pressured by higher stop loss medical costs; adjusted pre-tax income fell 47% in Q4.
  5. Evernorth adjusted revenues rose 32% for the year, with Specialty and Care Services adjusted pre-tax income up 15% and Pharmacy Benefit Services up 3%.
  6. 2025 guidance calls for adjusted income from operations of at least $7.9 billion ($29.50 per share) and adjusted revenues of at least $252 billion.
  7. Capital returns: $7.0 billion of buybacks in 2024, $10.3 billion total repurchase authority, and an 8% quarterly dividend increase to $1.51 per share.

03—Questions

Frequently Asked Questions

  1. Why did GAAP earnings fall so much in 2024 while adjusted earnings grew?

    GAAP shareholders' net income of $3.4 billion included a non-cash after-tax investment loss of $2.7 billion ($9.53 per share) from impairing VillageMD equity securities. Adjusted income excludes net investment gains and losses, amortization of acquired intangibles and special items, so it does not reflect this charge. Adjusted income from operations rose 4% to $7.7 billion.

  2. What is driving the weakness in Cigna Healthcare?

    Higher stop loss medical costs drove the medical care ratio up to 87.9% in Q4 2024 and 83.2% for the year, compared with 82.2% and 81.3% a year earlier. Adjusted pre-tax income from the segment fell 47% in Q4 and 6% for the full year. Management says it is taking corrective actions to address these near-term pressures.

  3. How strong is Evernorth's growth outlook?

    Evernorth is the main growth driver. Its 2024 adjusted revenues rose 32% to $202.2 billion, and adjusted pre-tax income rose 9% to $7.0 billion. Pharmacy Benefit Services revenues grew 46% on client wins, and Specialty and Care Services grew 18% on specialty volume and Humira biosimilar adoption. Management guides to at least $7.2 billion of Evernorth pre-tax adjusted income for 2025.

  4. What does the 2025 outlook assume, and what could change it?

    The outlook projects at least $7.9 billion of adjusted income from operations, or at least $29.50 per share, and assumes the Medicare business divestiture to HCSC closes in Q1 2025 and includes expected share repurchases. The guidance excludes any future business combinations and may change with net investment results, special items, medical cost trends and other risks described in the cautionary note.

  5. How is Cigna returning capital to shareholders?

    Cigna repurchased 20.9 million shares for about $7.0 billion in 2024. The board added $6.0 billion of incremental authorization, bringing total repurchase capacity to $10.3 billion as of December 31, 2024. The quarterly dividend rises 8% to $1.51 per share, payable March 20, 2025, and 2025 dividends are projected at about $1.6 billion.

04—Continue

← View all 8-K filings